CN102558189B - Refining method of methyhaaltrexone bromide - Google Patents
Refining method of methyhaaltrexone bromide Download PDFInfo
- Publication number
- CN102558189B CN102558189B CN201010594726.4A CN201010594726A CN102558189B CN 102558189 B CN102558189 B CN 102558189B CN 201010594726 A CN201010594726 A CN 201010594726A CN 102558189 B CN102558189 B CN 102558189B
- Authority
- CN
- China
- Prior art keywords
- methylnaltrexone bromide
- product
- methanol
- stirring
- finished product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 40
- 238000007670 refining Methods 0.000 title abstract description 20
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 title abstract 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 210
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- 238000000746 purification Methods 0.000 claims abstract description 23
- 239000012046 mixed solvent Substances 0.000 claims abstract description 13
- IFGIYSGOEZJNBE-LHJYHSJWSA-N (3s,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one;bromide Chemical compound [Br-].C([N@@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 IFGIYSGOEZJNBE-LHJYHSJWSA-N 0.000 claims description 124
- 229960002834 methylnaltrexone bromide Drugs 0.000 claims description 124
- 239000000047 product Substances 0.000 claims description 98
- 238000003756 stirring Methods 0.000 claims description 40
- 238000004809 thin layer chromatography Methods 0.000 claims description 38
- 239000007864 aqueous solution Substances 0.000 claims description 26
- 238000001291 vacuum drying Methods 0.000 claims description 24
- 239000012043 crude product Substances 0.000 claims description 21
- 239000012065 filter cake Substances 0.000 claims description 21
- 230000008569 process Effects 0.000 claims description 21
- 238000010438 heat treatment Methods 0.000 claims description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 13
- 238000012544 monitoring process Methods 0.000 claims description 13
- 239000000741 silica gel Substances 0.000 claims description 13
- 229910002027 silica gel Inorganic materials 0.000 claims description 13
- 239000000470 constituent Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 239000012264 purified product Substances 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 abstract description 10
- 238000010898 silica gel chromatography Methods 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000012071 phase Substances 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000002994 raw material Substances 0.000 description 10
- 239000007795 chemical reaction product Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 239000003513 alkali Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000003840 Opioid Receptors Human genes 0.000 description 3
- 108090000137 Opioid Receptors Proteins 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- -1 derivative of morphine ketone Chemical class 0.000 description 3
- 229940124636 opioid drug Drugs 0.000 description 3
- ZFSXKSSWYSZPGQ-UHFFFAOYSA-N (2-hydroxycyclopentyl)azanium;chloride Chemical compound Cl.NC1CCCC1O ZFSXKSSWYSZPGQ-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241001269238 Data Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229960000858 naltrexone hydrochloride Drugs 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 description 1
- IFGIYSGOEZJNBE-KNLJMPJLSA-N (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one;bromide Chemical compound [Br-].C[N+]1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)CC1CC1 IFGIYSGOEZJNBE-KNLJMPJLSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241001251200 Agelas Species 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- JPHGBESZBYAQRI-NLAHILFOSA-N OCCCC([C@@](CC1(C2)C(C3)N(CC4CC4)C1)(C3c1c2cc2)Oc1c2O)=O Chemical compound OCCCC([C@@](CC1(C2)C(C3)N(CC4CC4)C1)(C3c1c2cc2)Oc1c2O)=O JPHGBESZBYAQRI-NLAHILFOSA-N 0.000 description 1
- AMXCZHDPZRPZQM-OPBQOODWSA-N O[C@](CC1)(C(C2)[C@]2(C2)Cc3ccc4O)[C@]22c3c4O[C@H]2C1=O Chemical compound O[C@](CC1)(C(C2)[C@]2(C2)Cc3ccc4O)[C@]22c3c4O[C@H]2C1=O AMXCZHDPZRPZQM-OPBQOODWSA-N 0.000 description 1
- QZJVDKYKJOJQJO-XIEBXLSVSA-N O[C@](CC1)(C2N(CC3CC3)[C@@]2(C2)C3)C22c4c3ccc(O)c4O[C@H]2C1=O Chemical compound O[C@](CC1)(C2N(CC3CC3)[C@@]2(C2)C3)C22c4c3ccc(O)c4O[C@H]2C1=O QZJVDKYKJOJQJO-XIEBXLSVSA-N 0.000 description 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 229960002921 methylnaltrexone Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
The invention provides a refining method of methyhaaltrexone bromide, belonging to the technical field of chemical drug synthesis. According to the refining method, the methyhaaltrexone bromide is separated and purified by inverse silica gel column chromatography, and the procedure of recrystallization on a methyhaaltrexone bromide product by a mixed solvent of methanol and water can be added before and after the inverse silica gel column chromatography. According to the refining method, the conditions are mild, the yield is high, the purity of refined products is high, and the generated product meet the requirement on purification of medical methyhaaltrexone bromide preparation, so that the method is applicable to industrialized mass production.
Description
Technical field
The present invention relates to the process for purification of methylnaltrexone bromide, belong to chemicals synthesis technical field.
Background technology
Methylnaltrexone bromide (methyl naltrexone, MNTX) is a kind of selectivity mu opioid receptor antagonists, as a kind of quaternary ammonium salt, limit methylnaltrexone bromide by the ability of hemato encephalic barrier, make the opiate receptor antagonist of methylnaltrexone bromide as a kind of peripheral action, act on as in stomach intestinal tissue, therefore, methylnaltrexone bromide has reduced the constipation effect of opioid drug, and do not affect opioid drug to central nervous system analgesic activity.
Methylnaltrexone bromide has following characteristics: 1) acting on the μ acceptor of periphery, do not activate the opiate receptor of central nervous system, may be competitive antagonism; 2) safety, series of experiments does not all find that it has serious toxic side effect, common adverse reactions is stomachache, diarrhoea, flatulence and dizzy; 3) effect is fast, within several minutes, gets final product onset; 4) treatment constipation is than the logical purgatives of stool and tenderizer good effect; 5) action pathway is not unique, and directly the opiate receptor on gi tract is combined onset, can be combined with opiate receptor through the blood whole body that distributes yet.Therefore, methylnaltrexone bromide not only can be treated the gastrointestinal side-effect of opioid drug, also can treat parenteral untoward reaction; 6) not by hemato encephalic barrier, do not weaken the Central Analgesic Effect of opiate.
The compound name of methylnaltrexone bromide is called bromination-17-(cyclopropyl methyl)-4,5 α-epoxy-3,14-dihydroxyl-17-methyl-6-oxo morphinan, and its structural formula is as follows:
Methylnaltrexone bromide belongs to the derivative of morphine ketone, by the preparation were established of methylnaltrexone bromide is carried out to literature search and investigation, discovery is prepared methylnaltrexone bromide all taking Naltrexone Hydrochloride as raw material, and alkalization obtains free alkali, then methylates and obtain the finished product methylnaltrexone bromide.Induction-arrangement goes out its synthetic route and is broadly divided into three:
Synthetic route one (referring to Chinese patent application prospectus CN101516892A):
This route is first protected the phenolic hydroxyl group of TREXUPONT, then methyl, hydrogenation Deprotection, ion-exchange, bromination reaction synthesize target product methylnaltrexone bromide on methyl-sulfate.
Synthetic route two (referring to US Patent No. 4176186):
This route is first protected the phenolic hydroxyl group of TREXUPONT, then methyl, hydrolysis Deprotection, ion-exchange, bromination reaction synthesize target product methylnaltrexone bromide on methyl iodide.
Synthetic route three (referring to US Patent No. 4176186):
The free alkali that this technique syntheti c route is Naltrexone Hydrochloride directly carries out bromomethylation with monobromethane and reacts, and a step obtains product methylnaltrexone bromide.
From three circuits that methylnaltrexone bromide is synthetic above, the reaction reagent toxicity that synthetic route one adopts is larger, and synthesis condition is comparatively harsh, carries out and gets up to have certain difficulty; Synthetic route two is similar to synthetic route one principle, not too harsh but synthetic route two requires, and relatively easily carries out; Synthetic route three steps are the shortest, and intermediate is quality controllable, and just the by product in the finished product is difficult to remove, and therefore, adopt synthetic route three, for obtaining high-quality methylnaltrexone bromide product needed, thick product refined.
In US4176186 embodiment 5, specifically disclose the method that is prepared as follows of methylnaltrexone bromide: in reactor, add 50ml anhydrous propanone, 0.5ml dimethyl formamide, mix, add 2.5g (7.35mmol) TREXUPONT alkali, add 4.25g (44.8mmol) monobromethane, room temperature confined reaction 21 days, after having reacted, concentrating under reduced pressure reaction solution, add methanol crystallization, methanol/ether recrystallization, obtains reaction product methylnaltrexone bromide.What in the method, FF adopted is the mode of traditional recrystallization, and shortcoming is: utilize the needed purity of high-quality methylnaltrexone bromide highly finished product that methylnaltrexone bromide product that the method obtains can not fulfilling medicinal.
Summary of the invention
The object of this invention is to provide a kind of new methylnaltrexone bromide process for purification.The process for purification mild condition of methylnaltrexone bromide of the present invention, yield is high, highly finished product purity is high, is applicable to industrialized production, and utilizes the methylnaltrexone bromide product that the inventive method obtains to meet the medicinal needed purity of high-quality methylnaltrexone bromide highly finished product.
Technical scheme of the present invention is as follows:
A process for purification for methylnaltrexone bromide, adopts reversed-phase silica gel column chromatography separation and purification methylnaltrexone bromide.
Further, the aqueous solution of methylnaltrexone bromide crude product is crossed reverse phase silica gel post by above-mentioned methylnaltrexone bromide process for purification, first with 1% methanol aqueous solution (volumn concentration, lower same) wash-out, with 5% methanol aqueous solution wash-out, thin-layer chromatography (TLC) monitoring, in the time there is principal constituent spot in thin-layer chromatography again, collect corresponding elutriant, the elutriant concentrating under reduced pressure of collection is obtained to product.The developping agent of wherein said thin-layer chromatography is ethyl acetate-sherwood oil-methanol mixed solvent, and three's volume ratio is ethyl acetate: sherwood oil: methyl alcohol=1: 1: 1.
The process for purification of above-mentioned methylnaltrexone bromide, before carrying out reversed-phase silica gel column chromatography, can have a preposition purification step: use the mixed solvent of first alcohol and water to carry out recrystallization purifying to methylnaltrexone bromide crude product.Common way is: methylnaltrexone bromide crude product is added in the mixed solvent of first alcohol and water, stirring heating makes it to dissolve, and then adds gac to reflux, be cooled to again room temperature, under stirring, separate out solid, filter, filter cake is drained by methanol wash, and vacuum-drying obtains white products.Wherein, described gac is preferably medicinal carbon, more preferably needle-use activated carbon, the methylnaltrexone bromide of pharmaceutically acceptable to prepare (particularly injection is used).In the mixed solvent of first alcohol and water, the volume ratio of first alcohol and water is preferably 3～5: 1, and more preferably 4: 1.The consumption of gac adds 5g gac with every 100mL solution and is advisable.Return time is preferably 30min.Vacuum drying temperature is preferably 80 DEG C, and the time is preferably 6h.
Methylnaltrexone bromide process for purification provided by the present invention, further, after reversed-phase silica gel column chromatography, has the purification step of a postposition: use the mixed solvent of first alcohol and water to carry out recrystallization purifying to methylnaltrexone bromide.Be generally that the methylnaltrexone bromide obtaining through reversed-phase silica gel column chromatography is added in the mixed solvent of first alcohol and water, stirring heating makes it to dissolve, and refluxes, then be cooled to room temperature, under stirring, separate out solid, filter, filter cake is drained by methanol wash, and vacuum-drying obtains purified product.Wherein, in the mixed solvent of first alcohol and water, the volume ratio of first alcohol and water is preferably 3～5: 1, and more preferably 4: 1; Return time is preferably 30min; Vacuum drying temperature is preferably 80 DEG C, and the time is preferably 6h.
The most preferably scheme of methylnaltrexone bromide process for purification provided by the present invention comprises following three steps:
1) methylnaltrexone bromide crude product is added in the mixed solvent that methyl alcohol and water volume ratio are 4: 1, stirring heating makes it to dissolve, after slightly cold, adding consumption is the needle-use activated carbon of 5% (g/mL), backflow 30min, then be cooled to stirring at room temperature 4h, filter, filter cake is drained by methanol wash, 80 DEG C of vacuum-drying 6h, obtain white products (methylnaltrexone bromide highly finished product 1).
2) by step 1) suitable quantity of water is crossed reverse phase silica gel post after dissolving for the product that obtains, first with 1% methanol aqueous solution wash-out, again with 5% methanol aqueous solution wash-out, thin-layer chromatography (TLC) monitoring, in the time there is principal constituent spot in thin-layer chromatography, collect corresponding elutriant, the elutriant concentrating under reduced pressure of collection is obtained to product (methylnaltrexone bromide highly finished product 2).
3) by step 2) obtain methylnaltrexone bromide product add in the mixed solvent that methyl alcohol and water volume ratio are 4: 1, stirring heating dissolve, backflow 30min, then be cooled to stirring at room temperature 4h, filter, filter cake is drained by methanol wash, 80 DEG C of vacuum-drying 6h, obtain purified product.
Methylnaltrexone bromide crude product involved in the present invention can use any synthetic method of the prior art to obtain; include but not limited to following method: under nitrogen protection; in there-necked flask, add 11.6g (34.0mmol) TREXUPONT alkali; 175mL anhydrous propanone, 23.2mLDMF, 11.4mL (208mmol) monobromethane; close nitrogen; 25 DEG C of confined reactions 21 days, TLC monitoring experiment process, developping agent is ethyl acetate-sherwood oil-methyl alcohol (volume ratio 1: 1: 1).Reacted rear concentrating under reduced pressure reaction solution to dry, add 150mL washing with acetone after suction filtration obtain methylnaltrexone bromide crude product.80 DEG C of vacuum-drying 6h, obtain 13.4g product, yield 90.17%.
The advantage of methylnaltrexone bromide process for purification of the present invention is:
(1) mild condition.The process for purification of methylnaltrexone bromide of the present invention adopts the method for reversed-phase silica gel column chromatography and methanol-water recrystallization, does not need High Temperature High Pressure, mild condition.
(2) yield is high.Experimental results show that (referring to the table 1-6 in embodiment), the process for purification of methylnaltrexone bromide of the present invention is under the prerequisite of purity that ensures finished product, and yield is higher.
(3) be applicable to industrialized production.The industrial equipment of reverse phase silica gel post is very ripe at present, and the process for purification of methylnaltrexone bromide of the present invention adopts reversed-phase silica gel column chromatography, simple to operate, is applicable to industrialized production.
(4) highly finished product purity is high.Referring to the table 7 in embodiment, the methylnaltrexone bromide finished product purity that process for purification of the present invention obtains is very high, exceed the purity that in prior art, methylnaltrexone bromide process for purification can reach, the purifying end product of methylnaltrexone bromide process for purification of the present invention is suitable as the raw material of medicinal methylnaltrexone bromide preparation.
Brief description of the drawings
Fig. 1 is the HPLC collection of illustrative plates of embodiment 1 methylnaltrexone bromide end product purity detecting;
Fig. 2 is the HPLC collection of illustrative plates of embodiment 5 methylnaltrexone bromide end product purity detecting.
Embodiment
Preparation example 1: methylnaltrexone bromide synthetic
Under nitrogen protection; in there-necked flask, add 11.6g (34.0mmol) TREXUPONT alkali, 175mL anhydrous propanone, 23.2mL DMF; 11.4mL (208mmol) monobromethane; close nitrogen, 25 DEG C of confined reactions 21 days, have reacted rear concentrating under reduced pressure reaction solution to dry; add suction filtration after 150mL washing with acetone; get 80 DEG C of vacuum-drying 6h of filter cake, obtain 13.4g methylnaltrexone bromide crude product, yield 90.17%.
Embodiment 1: methylnaltrexone bromide refining
In 250mL four-hole boiling flask, add 13.4g methylnaltrexone bromide crude product, 75mL methyl alcohol, 19mL pure water, stirring heating is dissolved, after slightly cold, add 0.7g needle-use activated carbon, backflow 30min, is cooled to stirring at room temperature 4h, filters, filter cake is drained by methanol wash, 80 DEG C of vacuum-drying 6h, obtain white products (being denoted as " methylnaltrexone bromide highly finished product 1 ") 10.4g, yield 77.61%.
Above-mentioned 10.4g methylnaltrexone bromide highly finished product 1 use suitable quantity of water is crossed reverse phase silica gel post after dissolving, first with 1% methanol aqueous solution wash-out, again with 5% methanol aqueous solution wash-out, thin-layer chromatography (TLC) monitoring, in the time there is principal constituent spot in thin-layer chromatography, collect corresponding elutriant, the elutriant concentrating under reduced pressure of collection is obtained to product (being denoted as " methylnaltrexone bromide highly finished product 2 ") 7.15g, yield 68.75%.
In 100mL four-hole boiling flask, add 7.15g methylnaltrexone bromide highly finished product 2,42.0mL methyl alcohol, 10.5mL pure water, stirring heating is dissolved, backflow 30min, be cooled to stirring at room temperature 4h, filter, filter cake is drained by methanol wash, 80 DEG C of vacuum-drying 6h, obtain white products (being denoted as " methylnaltrexone bromide highly finished product 3 ") 5.86g, yield 81.96%.
1h-NMR (500MHz d
6-DMSO δ ppm) 9.48 (s, 1H can D
2o exchange), 6.67 (s, 2H), 6.39 (s, 1H can D
2o exchange), 4.91 (s, 2H), 4.03 (d, J=3.5Hz 1H), 3.90 (dd, J=3.5, 13.5Hz 1H), 3.65 (s, 3H), 3.51 (d, J=20.5Hz1H), 3.32 (s, 1H), 3.05 (dd, J=4.5, 20.5Hz 1H), 2.97 (dt, J=4.5, 13.5Hz 1H), 2.91 (dt, J=5.5, 14.5Hz 1H), 2.75 (d, J=10.5Hz 1H), 2.08 (d, J=14.5Hz1H), 2.04 (d, J=14Hz 1H), 1.59 (d, J=10.5Hz 1H), 1.56 (dt, J=3.5, 14Hz 1H), 1.23～1.21 (m, 1H), 0.77～0.36 (m, 4H).
13C-NMR(125MHz?d
6-DMSOδppm)207.506，143.616，140.481，127.774，120.300，119.794，118.151，88.526，71.732，70.898，70.868，56.673，52.834，48.387，34.870，32.062，27.293，24.423，5.720，3.825，2.777。
Embodiment 2: methylnaltrexone bromide refining
In 250mL four-hole boiling flask, add 13.4g methylnaltrexone bromide crude product, 75mL methyl alcohol, 19mL pure water, stirring heating is dissolved, and adds 0.7g needle-use activated carbon after slightly cold, and backflow 30min, is cooled to stirring at room temperature 4h.Filter, filter cake is drained by methanol wash, and 80 DEG C of vacuum-drying 6h obtain white products (being denoted as " methylnaltrexone bromide highly finished product 1 ") 10.2g.
Above-mentioned 10.2g methylnaltrexone bromide highly finished product 1 use suitable quantity of water is crossed reverse phase silica gel post after dissolving, first with 1% methanol aqueous solution wash-out, again with 5% methanol aqueous solution wash-out, thin-layer chromatography (TLC) monitoring, in the time there is principal constituent spot in thin-layer chromatography, collect corresponding elutriant, the elutriant concentrating under reduced pressure of collection is obtained to product (being denoted as " methylnaltrexone bromide highly finished product 2 ") 7.05g.
Embodiment 3: methylnaltrexone bromide refining
13.4g methylnaltrexone bromide crude product is crossed reverse phase silica gel post after dissolving by suitable quantity of water, first with 1% methanol aqueous solution wash-out, again with 5% methanol aqueous solution wash-out, thin-layer chromatography (TLC) monitoring, in the time there is principal constituent spot in thin-layer chromatography, collect corresponding elutriant, the elutriant concentrating under reduced pressure of collection is obtained to product 7.25g.
Embodiment 4: methylnaltrexone bromide refining
13.4g methylnaltrexone bromide crude product is crossed reverse phase silica gel post after dissolving by suitable quantity of water, first with 1% methanol aqueous solution wash-out, again with 5% methanol aqueous solution wash-out, thin-layer chromatography (TLC) monitoring, in the time there is principal constituent spot in thin-layer chromatography, collect corresponding elutriant, the elutriant concentrating under reduced pressure of collection is obtained to product 7.30g.
In 100mL four-hole boiling flask, add above-mentioned 7.30g methylnaltrexone bromide product, 42.0mL methyl alcohol, 10.5mL pure water, stirring heating is dissolved, backflow 30min, be cooled to stirring at room temperature 4h, filter, filter cake is drained by methanol wash, 80 DEG C of vacuum-drying 6h, obtain white products 5.76g.
Embodiment 5: methylnaltrexone bromide refining
In reactor, add 90.7g methylnaltrexone bromide crude product, 508mL methyl alcohol, 127mL pure water, stirring heating is dissolved, after slightly cold, add gac 5g, backflow 30min, is cooled to stirring at room temperature 4h, filters, filter cake is drained by methanol wash, 80 DEG C of vacuum-drying 6h, obtain white products (being denoted as " methylnaltrexone bromide highly finished product 1 ") 71.9g, yield 79.3%.
71.9g methylnaltrexone bromide highly finished product 1 use suitable quantity of water is crossed reverse phase silica gel post after dissolving, first with 1% methanol aqueous solution wash-out, again with 5% methanol aqueous solution wash-out, thin-layer chromatography (TLC) monitoring, in the time there is principal constituent spot in thin-layer chromatography, collect corresponding elutriant, the elutriant concentrating under reduced pressure of collection is obtained to product (being denoted as " methylnaltrexone bromide highly finished product 2 ") 48.84g, yield 67.95%.
In reactor, add 48.84g methylnaltrexone bromide highly finished product 2,273.6mL methyl alcohol, 68.4mL pure water, stirring heating is dissolved, backflow 30min, be cooled to stirring at room temperature 4h, filter, filter cake is drained by methanol wash, 80 DEG C of vacuum-drying 6h, obtain white products (being denoted as " methylnaltrexone bromide highly finished product 3 ") 40.15g, yield 82.21%.
Embodiment 6: methylnaltrexone bromide refining
In reactor, add 74.4g methylnaltrexone bromide crude product, 416mL methyl alcohol, 104mL pure water, stirring heating is dissolved, after slightly cold, add gac 5g, backflow 30min, is cooled to stirring at room temperature 4h, filters, filter cake is drained by methanol wash, 80 DEG C of vacuum-drying 6h, obtain white products (being denoted as " methylnaltrexone bromide highly finished product 1 ") 56.5g, yield 76.0%.
56.5g methylnaltrexone bromide highly finished product 1 use suitable quantity of water is crossed reverse phase silica gel post after dissolving, first with 1% methanol aqueous solution wash-out, again with 5% methanol aqueous solution wash-out, thin-layer chromatography (TLC) monitoring, in the time there is principal constituent spot in thin-layer chromatography, collect corresponding elutriant, the elutriant concentrating under reduced pressure of collection is obtained to product (being denoted as " methylnaltrexone bromide highly finished product 2 ") 38.84g, yield 68.70%.
In reactor, add 38.84g methylnaltrexone bromide highly finished product 2,217.6mL methyl alcohol, 54.4mL pure water, stirring heating is dissolved, backflow 30min, be cooled to stirring at room temperature 4h, filter, filter cake is drained by methanol wash, 80 DEG C of vacuum-drying 6h, obtain white products (being denoted as " methylnaltrexone bromide highly finished product 3 ") 31.64g, yield 81.47%.
Embodiment 7: methylnaltrexone bromide refining
In reactor, add 481.04g methylnaltrexone bromide crude product, 2696mL methyl alcohol, 674mL pure water, stirring heating is dissolved, after slightly cold, add needle-use activated carbon 5g, backflow 30min, is cooled to stirring at room temperature 4h, filters, filter cake methanol wash is drained, 80 DEG C of vacuum-drying 6h, obtain white products (being denoted as " methylnaltrexone bromide highly finished product 1 ") 365.72g, yield 76.03%.
365.72g methylnaltrexone bromide highly finished product 1 use suitable quantity of water is crossed reverse phase silica gel post after dissolving, first with 1% methanol aqueous solution wash-out, again with 5% methanol aqueous solution wash-out, thin-layer chromatography (TLC) monitoring, in the time there is principal constituent spot in thin-layer chromatography, collect corresponding elutriant, the elutriant concentrating under reduced pressure of collection is obtained to product (being denoted as " methylnaltrexone bromide highly finished product 2 ") 251.76g, yield 68.84%.
In reactor, add 251.76g methylnaltrexone bromide highly finished product 2,1408mL methyl alcohol, 352mL pure water, stirring heating is dissolved, backflow 30min, be cooled to stirring at room temperature 4h, filter, filter cake is drained by methanol wash, 80 DEG C of vacuum-drying 6h, obtain white products (being denoted as " methylnaltrexone bromide highly finished product 3 ") 204.74g, yield 81.32%.
Embodiment 8: methylnaltrexone bromide refining
In reactor, add 488.81g methylnaltrexone bromide crude product, 2736mL methyl alcohol, 684mL pure water, stirring heating is dissolved, after slightly cold, add needle-use activated carbon 5g, backflow 30min, is cooled to stirring at room temperature 4h, filters, filter cake is drained by methanol wash, 80 DEG C of vacuum-drying 6h, obtain white products (being denoted as " methylnaltrexone bromide highly finished product 1 ") 371.52g, yield 76.00%.
371.52g methylnaltrexone bromide highly finished product 1 use suitable quantity of water is crossed reverse phase silica gel post after dissolving, first with 1% methanol aqueous solution wash-out, again with 5% methanol aqueous solution wash-out, thin-layer chromatography (TLC) monitoring, in the time there is principal constituent spot in thin-layer chromatography, collect corresponding elutriant, the elutriant concentrating under reduced pressure of collection is obtained to product (being denoted as " methylnaltrexone bromide highly finished product 2 ") 256.54g, yield 69.05%.
In reactor, add 256.54g methylnaltrexone bromide highly finished product 2,1440mL methyl alcohol, 360mL pure water, stirring heating is dissolved, backflow 30min, be cooled to stirring at room temperature 4h, filter, filter cake is drained by methanol wash, 80 DEG C of vacuum-drying 6h, obtain white products (being denoted as " methylnaltrexone bromide highly finished product 3 ") 207.21g, yield 80.77%.
Embodiment 9: methylnaltrexone bromide refining
In reactor, add 493.97g methylnaltrexone bromide crude product, 2768mL methyl alcohol, 692mL pure water, stirring heating is dissolved, after slightly cold, add needle-use activated carbon 5g, backflow 30min, is cooled to stirring at room temperature 4h, filters, filter cake is drained by methanol wash, 80 DEG C of vacuum-drying 6h, obtain white products (being denoted as " methylnaltrexone bromide highly finished product 1 ") 370.42g, yield 74.98%.
Product is crossed reverse phase silica gel post after dissolving by suitable quantity of water, first with 1% methanol aqueous solution wash-out, again with 5% methanol aqueous solution wash-out, thin-layer chromatography (TLC) monitoring, in the time there is principal constituent spot in thin-layer chromatography, collect corresponding elutriant, the elutriant concentrating under reduced pressure of collection is obtained to product (being denoted as " methylnaltrexone bromide highly finished product 2 ") 256.09g, yield 69.14%.
In reactor, add 256.09g methylnaltrexone bromide crude product, 1432mL methyl alcohol, 358mL pure water, stirring heating is dissolved, backflow 30min, be cooled to stirring at room temperature 4h, filter, filter cake is drained by methanol wash, 80 DEG C of vacuum-drying 6h, obtain white products (being denoted as " methylnaltrexone bromide highly finished product 3 ") 206.63g, yield 80.68%.
Data to above-described embodiment and result are summarized and are analyzed below, feasibility and the stability of checking process for refining of the present invention.
Three batches of product lab scale datas:
Table 1: refining 1 (raw material: methylnaltrexone bromide crude product) of finished product
Table 2: refining 2 (raw materials: methylnaltrexone bromide highly finished product 1) of finished product
Table 3: refining 3 (raw materials: methylnaltrexone bromide highly finished product 2) of finished product
Three batches of product amplification quantity datas:
Table 4: refining 1 (raw material: methylnaltrexone bromide crude product) of finished product
Table 5: refining 2 (raw materials: methylnaltrexone bromide highly finished product 1) of finished product
Table 6: refining 3 (raw materials: methylnaltrexone bromide highly finished product 2) of finished product
The quality control inspection of the purifying end product of methylnaltrexone bromide:
Proterties: colourless crystallization powder
HPLC detects: high performance liquid phase instrument model: Aqilent 1100 type high performance liquid chromatographs
Chromatographic condition: chromatographic column: Agela Akasil C
18, 5 μ m, 4.6 × 250mm
Moving phase: methyl alcohol: 0.15% trifluoroacetic acid aqueous solution=22: 78
Detect wavelength: 230nm
Flow velocity: 1.0mL/min
Sample size: 20 μ L
Column temperature: 30 DEG C
Theoretical plate number: press methylnaltrexone bromide and calculate, should be not less than 3000.
HPLC method detected result is in table 7.
Table 7: the quality control of the purifying end product of methylnaltrexone bromide and with the comparison of US4176186 recrystallization method:
Note: US4176186 recrystallization method is: methylnaltrexone bromide crude product is first used methanol crystallization, then use methanol/ether recrystallization, obtain product methylnaltrexone bromide.
Can see by above data, the purifying end product content of methylnaltrexone bromide process for purification of the present invention and related substance (impurity) have all reached higher standard, be suitable as the raw material of medicinal methylnaltrexone bromide preparation, and the purifying end product content of the methylnaltrexone bromide that US4176186 recrystallization method obtains is lower, related substance (impurity) is more, is not suitable as the raw material of medicinal methylnaltrexone bromide preparation.
The technique that three batches of lab scales (embodiment 1,5 and 6) are established is reappeared through three batches of pilot scales (embodiment 7,8 and 9), shows that this technique circulation ratio is good, products obtained therefrom steady quality.Figure of description 1,2 is shown in by the purity detecting HPLC collection of illustrative plates of embodiment 1 and embodiment 5 end products.
Claims (2)
1. a process for purification for methylnaltrexone bromide, comprises the following steps:
1) methylnaltrexone bromide crude product is added in the mixed solvent that methyl alcohol and water volume ratio are 4: 1, stirring heating makes it to dissolve, and then adds needle-use activated carbon, backflow 30min, then be cooled to stirring at room temperature 4h, filter, filter cake is drained by methanol wash, and 80 DEG C of vacuum-drying 6h, obtain white products;
2) product step 1) being obtained is with crossing reverse phase silica gel post after water dissolution, first with 1% methanol aqueous solution wash-out, then with 5% methanol aqueous solution wash-out, thin-layer chromatography monitoring, in the time there is principal constituent spot in thin-layer chromatography, collect corresponding elutriant, the elutriant concentrating under reduced pressure of collection is obtained to product;
3) by step 2) obtain product add in the mixed solvent that methyl alcohol and water volume ratio are 4: 1, stirring heating dissolve, backflow 30min, is then cooled to stirring at room temperature 4h, filter, filter cake is drained by methanol wash, 80 DEG C of vacuum-drying 6h, obtain purified product.
2. process for purification as claimed in claim 1, is characterized in that step 2) described in the developping agent of thin-layer chromatography be that volume ratio is ethyl acetate-sherwood oil-methanol mixed solvent of 1: 1: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010594726.4A CN102558189B (en) | 2010-12-17 | 2010-12-17 | Refining method of methyhaaltrexone bromide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010594726.4A CN102558189B (en) | 2010-12-17 | 2010-12-17 | Refining method of methyhaaltrexone bromide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102558189A CN102558189A (en) | 2012-07-11 |
| CN102558189B true CN102558189B (en) | 2014-09-03 |
Family
ID=46404934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010594726.4A Expired - Fee Related CN102558189B (en) | 2010-12-17 | 2010-12-17 | Refining method of methyhaaltrexone bromide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102558189B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108976240B (en) * | 2017-06-02 | 2021-03-02 | 扬子江药业集团有限公司 | Refining method of methylnaltrexone bromide |
| CN111777617A (en) * | 2020-07-10 | 2020-10-16 | 华润三九医药股份有限公司 | Refining method of methylnaltrexone bromide |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100379741C (en) * | 2002-11-08 | 2008-04-09 | 马林克罗特公司 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts |
| AR057035A1 (en) * | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES |
| CN101607963B (en) * | 2008-06-20 | 2013-04-03 | 重庆医药工业研究院有限责任公司 | Morphinan derivatives and preparation method thereof |
| MX2011011245A (en) * | 2009-04-24 | 2012-04-11 | Univ Brock | Processes for the preparation of morphinane and morphinone compounds. |
-
2010
- 2010-12-17 CN CN201010594726.4A patent/CN102558189B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102558189A (en) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102020635B (en) | Preparation method of hydrochloride Fasudil hemihydrate | |
| CN108794351A (en) | A kind of preparation method of Mo Fanselin key intermediate | |
| CN102503805A (en) | Method for preparing 4-felbinac through rearrangement reaction | |
| CN102558189B (en) | Refining method of methyhaaltrexone bromide | |
| CN105524127A (en) | Gastrodin compound and preparation thereof | |
| CN103242286A (en) | Bicyclol medical composition and preparation method thereof | |
| CN102816085B (en) | Preparation method of iohexol impurity | |
| CN104940216A (en) | Application of galloyl-glucoside derivative and pharmaceutical composition for treating hyperuricemia | |
| CN104628803A (en) | Total synthesis method for rape pollen alkali A and caper alkali B and analogues thereof | |
| CN102432516B (en) | Method for refining oxiracetam | |
| CN110655506B (en) | Preparation method of tegafur | |
| CN106243050B (en) | A kind of method of suitable industrialized production Clobazam | |
| CN104887675A (en) | Application of [(aryloxy)(heteroaryl)]methyl piperidine derivative in preparation of depression treatment drugs | |
| CN107021978B (en) | A kind of methylnaltrexone bromide and its new preparation method of intermediate | |
| CN105399638A (en) | Amino sugar intermediate preparation method | |
| CN101195602A (en) | 1-deoxidization nojiri toxin derivant, production method and uses thereof | |
| CN100415742C (en) | Novel hydrochloride compound and use thereof | |
| CN110698532B (en) | Method for extracting sea cucumber saponin Cladoloside A | |
| CN104163769B (en) | A kind of preparation method of chlorination propionyl-L-carnitine | |
| CN102558188B (en) | Preparation method of methyhaaltrexone bromide | |
| CN104447649B (en) | Methyl naphtho-[1,2-b] amide compounds and pharmaceutically acceptable salt and its preparation method and application thereof | |
| CN103739635A (en) | Method for purifying 1,3,4,6-tetra-O-acetyl-2-O-triflat-beta-D-mannopyranose intermediate | |
| CN106977561A (en) | Sutherlandin-5-p-hydroxybenzoate preparation and its application in drugs for rheumatoid arthritis is prepared | |
| CN106977560A (en) | 2S-cardiospermin-5-benzoate preparation and its application in drugs for rheumatoid arthritis is prepared | |
| CN107698582A (en) | A kind of synthetic method of tetrabenazine and its intermediate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 100871, Beijing, Haidian District Cheng Fu Road 298, founder building, 5 floor Patentee after: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee after: PKUCARE PHARMACEUTICAL R&D CENTER Patentee after: PKU HEALTHCARE INDUSTRY Group Address before: 100871, Beijing, Haidian District Cheng Fu Road 298, founder building, 5 floor Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: PKUCARE PHARMACEUTICAL R&D CENTER Patentee before: Pku Healthcare Industry Group Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221017 Address after: 3007, Hengqin international financial center building, No. 58, Huajin street, Hengqin new area, Zhuhai, Guangdong 519031 Patentee after: New founder holdings development Co.,Ltd. Patentee after: PKUCARE PHARMACEUTICAL R&D CENTER Patentee after: Peking University Medical Management Co.,Ltd. Address before: 100871, Beijing, Haidian District Cheng Fu Road 298, founder building, 5 floor Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: PKUCARE PHARMACEUTICAL R&D CENTER Patentee before: PKU HEALTHCARE INDUSTRY Group |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140903 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |